De novo autoimmune hepatitis subsequent to switching from type 2b to type 2a alpha-pegylated interferon treatment for recurrent hepatitis C after liver transplantation: Report of a case

Surgery Today

Volumn 41, Issue 7, 2011, Pages 1016-1019

  Takeishi, Kazuki ^a   Shirabe, Ken ^a   Toshima, Takeo ^a   Ikegami, Toru ^a   Morita, Kazutoyo ^a   Fukuhara, Takasuke ^a   Motomura, Takashi ^a   Mano, Yohei ^a   Uchiyama, Hideaki ^a   Soejima, Yuji ^a   Taketomi, Akinobu ^a   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Autoimmune hepatitis; Liver transplantation; Pegylated interferon

Indexed keywords

ALANINE AMINOTRANSFERASE; BASILIXIMAB; CYCLOSPORIN A; HLA ANTIGEN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PREDNISOLONE; RIBAVIRIN; SULFAMETHOXAZOLE; TACROLIMUS; TRIMETHOPRIM; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIBODY TITER; ANTIVIRAL THERAPY; ARTICLE; ARTIFICIAL VENTILATION; AUTOIMMUNE HEPATITIS; CASE REPORT; CONTINUOUS HEMODIALYSIS; DRUG DOSE REDUCTION; DRUG PULSE THERAPY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY INFILTRATE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER GRAFT REJECTION; LIVER HISTOLOGY; LIVER TRANSPLANTATION; LIVING DONOR; MALE; MULTIPLE ORGAN FAILURE; PNEUMOCYSTIS PNEUMONIA; RECURRENT VIRUS INFECTION; RESPIRATORY DISTRESS; RISK FACTOR; TREATMENT DURATION;

ANTIVIRAL AGENTS; BIOPSY; HEPATITIS C, CHRONIC; HEPATITIS, AUTOIMMUNE; HUMANS; INTERFERON-ALPHA; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RECURRENCE;

EID: 79960334474     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-010-4392-z     Document Type: Article

References (16)

1. L.M. Forman J.D. Lewis J.A. Berlin H.I. Feldman M.R. Lucey 2002 The association between hepatitis C infection and survival after orthotopic liver transplantation Gastroenterology 122 889 896 11910340 10.1053/gast.2002.32418 (Pubitemid 34267271)
2. K. Hasegawa N. Kokudo 2009 Surgical treatment of hepatocellular carcinoma Surg Today 39 833 843 19784720 10.1007/s00595-008-4024-z
3. J. Dumortier J.Y. Scoazec P. Chevallier O. Boillot 2004 Treatment of recurrent hepatitis after liver transplantation - a pilot study of peginterferon alfa-2b and ribavirin combination J Hepatol 40 669 674 15030984 10.1016/j.jhep.2003.12.015 1:CAS:528:DC%2BD2cXitFKhsLY%3D (Pubitemid 38367790)
4. D.B. Strader T. Wright D.L. Thomas L.B. Seeff 2004 Diagnosis, management, and treatment of hepatitis C Hepatology 39 1147 1171 15057920 10.1002/hep.20119 (Pubitemid 38428955)
5. M.P. Manns H. Wedemeyer M. Cornberg 2006 Treating viral hepatitis C: efficacy, side effects, and complications Gut 55 1350 1359 16905701 10.1136/gut.2005.076646 1:CAS:528:DC%2BD28XhtVehurfE (Pubitemid 44277369)
6. B. Conrad 2003 Potential mechanisms of interferon-alpha induced autoimmunity Autoimmunity 36 519 523 14984029 10.1080/08916930310001602137 1:CAS:528:DC%2BD3sXptVOhtro%3D (Pubitemid 37498248)
7. S. Berardi F. Lodato A. Gramenzi A. D'Errico M. Lenzi A. Bontadini, et al. 2007 High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon-alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? Gut 56 237 242 16798778 10.1136/gut.2006.092064 1:CAS:528:DC%2BD2sXivF2gt7Y%3D
8. E. Cholongitas D. Samonakis D. Patch M. Senzolo A.K. Burroughs A. Quaglia, et al. 2006 Induction of autoimmune hepatitis by pegylated interferon in a liver transplant patient with recurrent hepatitis C virus Transplantation 81 488 490 16477242 10.1097/01.tp.0000196716.07188.c4 (Pubitemid 43255742)
9. N. Kontorinis K. Agarwal N. Elhajj M.I. Fiel T.D. Schiano 2006 Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation Liver Transpl 12 827 830 16628699 10.1002/lt.20706
10. M. Merli F. Gentili M. Giusto A.F. Attili S.G. Corradini G. Mennini, et al. 2009 Immune-mediated liver dysfunction after antiviral treatment in liver transplanted patients with hepatitis C: allo or autoimmune de novo hepatitis? Dig Liver Dis 41 345 349 19162574 10.1016/j.dld.2008.09.015 1:STN:280: DC%2BD1M3ltlOnuw%3D%3D
11. J.A. Todd H. Acha-Orbea J.I. Bell N. Chao Z. Fronek C.O. Jacob, et al. 1988 A molecular basis for MHC class II-associated autoimmunity Science 240 1003 1009 3368786 10.1126/science.3368786 1:CAS:528:DyaL1cXkt1Whtr0%3D
12. Y. Oppenheim Y. Ban Y. Tomer 2004 Interferon induced autoimmune thyroid disease: a model for human autoimmunity Autoimmunity Rev 3 388 393 10.1016/j.autrev.2004.03.003 1:CAS:528:DC%2BD2cXosFyrsbw%3D (Pubitemid 38993361)
13. L. Fernandez-Soto A. Gonzalez F. Escobar-Jimenez R. Vazquez E. Ocete N. Olea, et al. 1998 Increased risk of autoimmune thyroid disease in hepatitis C vs. hepatitis B before, during, and after discontinuing interferon therapy Arch Intern Med 158 1445 1448 9665354 10.1001/archinte.158.13.1445 1:CAS:528:DyaK1cXkslSru74%3D (Pubitemid 28317761)
14. S. Brawn N. Tare T. Inoue M. Yamasaki M. Okabe I. Horii, et al. 1999 Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein Exp Hematol 27 425 432 10.1016/S0301-472X(98)00051-4 (Pubitemid 29125050)
15. T. Yamaoka Y. Tabata Y. Ikeda 1994 Distribution and tissue uptake of poly (ethylene glycol) with different molecular weights after intravenous administration to mice J Pharm Sci 83 601 606 8046623 10.1002/jps.2600830432 1:CAS:528:DyaK2cXhslehs78%3D (Pubitemid 24222392)
16. M. Sherman E.M. Yoshida M. Deschenes M. Krajden V.G. Bain K. Peltekian, et al. 2006 Peginterferon alpha-2a (40 KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy Gut 55 1631 1638 16709661 10.1136/gut.2005.083113 1:CAS:528:DC%2BD28Xht1GkurjM (Pubitemid 44629215)